Antecedent aspirin therapy inhibits baseline platelet activity in patients presenting with acute myocardial infarction

Victor L. Serebruany, Raymond D. Bahr, Christopher M. O'Connor, David R. Lowry, Paul A. Gurbel

Research output: Contribution to journalArticle

Abstract

Aspirin therapy and platelet inhibition reduce the risk for the development of acute myocardial infarction (AMI). However, the effects of aspirin on baseline platelet activity in patients presenting with AMI are not known. We determined the effect of long-term aspirin use on baseline platelet activity in patients presenting with AMI, enrolled in the GUSTO-III Platelet Study. Platelet characteristics were investigated by aggregometry, flow cytometry and enzyme-linked immunosorbent assay in 23 patients before thrombolysis. Sixteen AMI patients were aspirin free, and 7 patients were using aspirin (81-500 mg/daily). The aspirin-treated patients exhibited a mild but consistent reduction of platelet activity which reached significance for 5 μM (p = 0.02), and 10 μM (p = 0.01) adenosine diphosphate induced aggregation. The surface expression of P-selectin (p = 0.02) and PECAM-1 (p = 0.03) and the plasma level of soluble P-selectin (p = 0.02) were also reduced. As previously observed in normal humans and patients with stable coronary artery disease, long-term aspirin therapy is also associated with diminished platelet activation in patients presenting with AMI. Long-term aspirin therapy mildly reduces baseline platelet activity; however, this degree of relative platelet inhibition does not appear to be cardioprotective.

Original languageEnglish (US)
Pages (from-to)37-42
Number of pages6
JournalCardiology
Volume90
Issue number1
DOIs
StatePublished - Jul 1998

Fingerprint

Aspirin
Blood Platelets
Myocardial Infarction
P-Selectin
Therapeutics
CD31 Antigens
Platelet Activation
Adenosine Diphosphate
Coronary Artery Disease
Flow Cytometry
Enzyme-Linked Immunosorbent Assay

Keywords

  • Acute myocardial infarction
  • Aspirin
  • Platelets

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Antecedent aspirin therapy inhibits baseline platelet activity in patients presenting with acute myocardial infarction. / Serebruany, Victor L.; Bahr, Raymond D.; O'Connor, Christopher M.; Lowry, David R.; Gurbel, Paul A.

In: Cardiology, Vol. 90, No. 1, 07.1998, p. 37-42.

Research output: Contribution to journalArticle

Serebruany, Victor L. ; Bahr, Raymond D. ; O'Connor, Christopher M. ; Lowry, David R. ; Gurbel, Paul A. / Antecedent aspirin therapy inhibits baseline platelet activity in patients presenting with acute myocardial infarction. In: Cardiology. 1998 ; Vol. 90, No. 1. pp. 37-42.
@article{64b02136b93f4daa93cd88cfb3ad6b1a,
title = "Antecedent aspirin therapy inhibits baseline platelet activity in patients presenting with acute myocardial infarction",
abstract = "Aspirin therapy and platelet inhibition reduce the risk for the development of acute myocardial infarction (AMI). However, the effects of aspirin on baseline platelet activity in patients presenting with AMI are not known. We determined the effect of long-term aspirin use on baseline platelet activity in patients presenting with AMI, enrolled in the GUSTO-III Platelet Study. Platelet characteristics were investigated by aggregometry, flow cytometry and enzyme-linked immunosorbent assay in 23 patients before thrombolysis. Sixteen AMI patients were aspirin free, and 7 patients were using aspirin (81-500 mg/daily). The aspirin-treated patients exhibited a mild but consistent reduction of platelet activity which reached significance for 5 μM (p = 0.02), and 10 μM (p = 0.01) adenosine diphosphate induced aggregation. The surface expression of P-selectin (p = 0.02) and PECAM-1 (p = 0.03) and the plasma level of soluble P-selectin (p = 0.02) were also reduced. As previously observed in normal humans and patients with stable coronary artery disease, long-term aspirin therapy is also associated with diminished platelet activation in patients presenting with AMI. Long-term aspirin therapy mildly reduces baseline platelet activity; however, this degree of relative platelet inhibition does not appear to be cardioprotective.",
keywords = "Acute myocardial infarction, Aspirin, Platelets",
author = "Serebruany, {Victor L.} and Bahr, {Raymond D.} and O'Connor, {Christopher M.} and Lowry, {David R.} and Gurbel, {Paul A.}",
year = "1998",
month = "7",
doi = "10.1159/000006814",
language = "English (US)",
volume = "90",
pages = "37--42",
journal = "Journal of Cardiovascular Medicine",
issn = "1558-2027",
publisher = "Lippincott Williams and Wilkins Ltd.",
number = "1",

}

TY - JOUR

T1 - Antecedent aspirin therapy inhibits baseline platelet activity in patients presenting with acute myocardial infarction

AU - Serebruany, Victor L.

AU - Bahr, Raymond D.

AU - O'Connor, Christopher M.

AU - Lowry, David R.

AU - Gurbel, Paul A.

PY - 1998/7

Y1 - 1998/7

N2 - Aspirin therapy and platelet inhibition reduce the risk for the development of acute myocardial infarction (AMI). However, the effects of aspirin on baseline platelet activity in patients presenting with AMI are not known. We determined the effect of long-term aspirin use on baseline platelet activity in patients presenting with AMI, enrolled in the GUSTO-III Platelet Study. Platelet characteristics were investigated by aggregometry, flow cytometry and enzyme-linked immunosorbent assay in 23 patients before thrombolysis. Sixteen AMI patients were aspirin free, and 7 patients were using aspirin (81-500 mg/daily). The aspirin-treated patients exhibited a mild but consistent reduction of platelet activity which reached significance for 5 μM (p = 0.02), and 10 μM (p = 0.01) adenosine diphosphate induced aggregation. The surface expression of P-selectin (p = 0.02) and PECAM-1 (p = 0.03) and the plasma level of soluble P-selectin (p = 0.02) were also reduced. As previously observed in normal humans and patients with stable coronary artery disease, long-term aspirin therapy is also associated with diminished platelet activation in patients presenting with AMI. Long-term aspirin therapy mildly reduces baseline platelet activity; however, this degree of relative platelet inhibition does not appear to be cardioprotective.

AB - Aspirin therapy and platelet inhibition reduce the risk for the development of acute myocardial infarction (AMI). However, the effects of aspirin on baseline platelet activity in patients presenting with AMI are not known. We determined the effect of long-term aspirin use on baseline platelet activity in patients presenting with AMI, enrolled in the GUSTO-III Platelet Study. Platelet characteristics were investigated by aggregometry, flow cytometry and enzyme-linked immunosorbent assay in 23 patients before thrombolysis. Sixteen AMI patients were aspirin free, and 7 patients were using aspirin (81-500 mg/daily). The aspirin-treated patients exhibited a mild but consistent reduction of platelet activity which reached significance for 5 μM (p = 0.02), and 10 μM (p = 0.01) adenosine diphosphate induced aggregation. The surface expression of P-selectin (p = 0.02) and PECAM-1 (p = 0.03) and the plasma level of soluble P-selectin (p = 0.02) were also reduced. As previously observed in normal humans and patients with stable coronary artery disease, long-term aspirin therapy is also associated with diminished platelet activation in patients presenting with AMI. Long-term aspirin therapy mildly reduces baseline platelet activity; however, this degree of relative platelet inhibition does not appear to be cardioprotective.

KW - Acute myocardial infarction

KW - Aspirin

KW - Platelets

UR - http://www.scopus.com/inward/record.url?scp=0031872813&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031872813&partnerID=8YFLogxK

U2 - 10.1159/000006814

DO - 10.1159/000006814

M3 - Article

VL - 90

SP - 37

EP - 42

JO - Journal of Cardiovascular Medicine

JF - Journal of Cardiovascular Medicine

SN - 1558-2027

IS - 1

ER -